{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:15:43Z","timestamp":1790806543948,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaad.2026.02.096","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:27:41Z","timestamp":1772483261000},"page":"1731-1737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of oral JAK inhibitors combined with 308-nm excimer laser in pediatric progressive vitiligo: A multicenter study"],"prefix":"10.1016","volume":"94","author":[{"given":"Shuying","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoyao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jaad.2026.02.096_bib1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Kr\u00fcger","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2026.02.096_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.096_bib3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1203475419833609","article-title":"The use of Janus kinase inhibitors in vitiligo: a review of the literature","volume":"23","author":"Relke","year":"2019","journal-title":"J Cutan Med Surg"},{"issue":"17","key":"10.1016\/j.jaad.2026.02.096_bib4","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.3390\/jcm13175225","article-title":"Vitiligo: from pathogenesis to treatment","volume":"13","author":"Speeckaert","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.096_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jaad.2010.10.043","article-title":"Vitiligo: a comprehensive overview part II: treatment options and approach to treatment","volume":"65","author":"Felsten","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.02.096_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1119427","article-title":"Glucocorticoid induced bone disorders in children: research progress in treatment mechanisms","volume":"14","author":"Hua","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.096_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/0378-6323.62959","article-title":"Topical corticosteroid use in children: adverse effects and how to minimize them","volume":"76","author":"Saraswat","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"10.1016\/j.jaad.2026.02.096_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40257-019-00430-0","article-title":"Childhood vitiligo","volume":"20","author":"Nicolaidou","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2026.02.096_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2025.1550349","article-title":"Dermoscopic features in children with vitiligo and other hypopigmentation disorders","volume":"13","author":"Yu","year":"2025","journal-title":"Front Pediatr"},{"issue":"4S2","key":"10.1016\/j.jaad.2026.02.096_bib10","article-title":"Vitiligo: current therapies and future treatments","volume":"13","author":"Seneschal","year":"2023","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.096_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2302064","article-title":"Comparison of various excimer laser (EL) combination therapies for vitiligo: a systematic review and network meta-analysis","volume":"35","author":"Li","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.096_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2296851","article-title":"Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial","volume":"35","author":"Alshiyab","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.096_bib13","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/pde.13726","article-title":"The effectiveness of topical therapy combined with 308-nm excimer laser on vitiligo compared to excimer laser monotherapy in pediatric patients","volume":"36","author":"Li","year":"2019","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.02.096_bib14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2004.05.036","article-title":"Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases","volume":"51","author":"Silverberg","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2026.02.096_bib15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/ijd.17157","article-title":"Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review","volume":"63","author":"Utama","year":"2024","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2026.02.096_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606456","article-title":"Type I interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways","volume":"11","author":"Mazewski","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jaad.2026.02.096_bib17","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.02.096_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/15593258221105370","article-title":"Baricitinib is effective in treating progressing Vitiligo in vivo and in vitro","volume":"20","author":"Dong","year":"2022","journal-title":"Dose Response"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.096_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jid.2020.04.027","article-title":"Jak inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells","volume":"141","author":"Azzolino","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.096_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.096_bib21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaad.2023.05.001","article-title":"Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study","volume":"89","author":"Chiricozzi","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.096_bib22","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.096_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3889\/oamjms.2018.042","article-title":"Micro - focused phototherapy associated to Janus kinase inhibitor: a promising valid therapeutic option for patients with localized vitiligo","volume":"6","author":"Gianfaldoni","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"issue":"10","key":"10.1016\/j.jaad.2026.02.096_bib24","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/CM9.0000000000000794","article-title":"Deciphering skin re-pigmentation patterns in vitiligo: an update on the cellular and molecular events involved","volume":"133","author":"Lei","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.096_bib25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jdv.18005","article-title":"The use of lasers in vitiligo, an overview","volume":"36","author":"Post","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2026.02.096_bib26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/CCID.S396430","article-title":"Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB-UVB phototherapy","volume":"16","author":"Li","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2026.02.096_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15821","article-title":"Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice","volume":"35","author":"Song","year":"2022","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.jaad.2026.02.096_bib28","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/jdv.19162","article-title":"Topical ruxolitinib: a new treatment for vitiligo","volume":"37","author":"Tavoletti","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"02","key":"10.1016\/j.jaad.2026.02.096_bib29","first-page":"102","article-title":"Analysis of baricitinib efficacy in treating progressive vitiligo","volume":"39","author":"Li","year":"2023","journal-title":"Chin J Lepr Skin Dis"},{"issue":"4","key":"10.1016\/j.jaad.2026.02.096_bib30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4103\/ijd.ijd_515_23","article-title":"Use of oral tofacitinib in the treatment of pediatric vitiligo: a case series","volume":"69","author":"Biswal","year":"2024","journal-title":"Indian J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.096_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","article-title":"Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis","volume":"33","author":"Phan","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.096_bib32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/1523-1747.ep12480997","article-title":"Role of hair follicles in the repigmentation of vitiligo","volume":"97","author":"Cui","year":"1991","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2026.02.096_bib33","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/jdv.19362","article-title":"A randomized prospective study to assess the role of topical tacrolimus as preventive therapy in unstable acral vitiligo","volume":"37","author":"Kumar","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2026.02.096_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2021.07.021","article-title":"Repigmentation of vitiligo-associated eyelash leukotrichia with topical tofacitinib","volume":"16","author":"Kim","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"10401","key":"10.1016\/j.jaad.2026.02.096_bib35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial","volume":"402","author":"Ramanan","year":"2023","journal-title":"Lancet"},{"issue":"10315","key":"10.1016\/j.jaad.2026.02.096_bib36","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jaad.2026.02.096_bib37","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/jdv.20639","article-title":"European guideline (EuroGuiDerm) on atopic eczema: living update","volume":"39","author":"Wollenberg","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2026.02.096_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.096_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2025.2514637","article-title":"Comparative efficacy and safety of targeted narrowband ultraviolet B, 308-nm excimer laser, and 308-nm excimer lamp in vitiligo: a retrospective study","volume":"36","author":"Tantivithiwate","year":"2025","journal-title":"J Dermatolog Treat"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222600321X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222600321X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:05:21Z","timestamp":1779192321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222600321X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S019096222600321X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.096","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of oral JAK inhibitors combined with 308-nm excimer laser in pediatric progressive vitiligo: A multicenter study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}